These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 18580315)

  • 21. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
    Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
    Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
    Davidson B; Reich R; Lazarovici P; Nesland JM; Skrede M; Risberg B; Tropé CG; Flørenes VA
    Clin Cancer Res; 2003 Jun; 9(6):2248-59. PubMed ID: 12796393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of epidermal growth factor receptor and cyclin D1 in pretreatment biopsies as a predictive factor of radiotherapy efficacy in early glottic cancer.
    Chang AR; Wu HG; Park CI; Jun YK; Kim CW
    Head Neck; 2008 Jul; 30(7):852-7. PubMed ID: 18302259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. E-Cadherin complex protein expression and survival in ovarian carcinoma.
    Davidson B; Gotlieb WH; Ben-Baruch G; Nesland JM; Bryne M; Goldberg I; Kopolovic J; Berner A
    Gynecol Oncol; 2000 Dec; 79(3):362-71. PubMed ID: 11104606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors.
    Barbieri F; Cagnoli M; Ragni N; Foglia G; Bruzzo C; Pedullà F; Alama A
    Clin Cancer Res; 1999 Jul; 5(7):1837-42. PubMed ID: 10430089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
    Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
    Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization.
    Diebold J; Mösinger K; Peiro G; Pannekamp U; Kaltz C; Baretton GB; Meier W; Löhrs U
    J Pathol; 2000 Apr; 190(5):564-71. PubMed ID: 10727982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas.
    Levidou G; Korkolopoulou P; Thymara I; Vassilopoulos I; Saetta AA; Gakiopoulou H; Konstantinidou A; Kairi-Vassilatou E; Pavlakis K; Patsouris E
    Int J Gynecol Pathol; 2007 Oct; 26(4):410-7. PubMed ID: 17885491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
    Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
    Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclooxygenase 2 expression in serous tumors of the ovary.
    Singhal PK; Spiegel G; Driscoll D; Odunsi K; Lele S; Rodabaugh KJ
    Int J Gynecol Pathol; 2005 Jan; 24(1):62-6. PubMed ID: 15626918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
    Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
    Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
    Wong KK; Lu KH; Malpica A; Bodurka DC; Shvartsman HS; Schmandt RE; Thornton AD; Deavers MT; Silva EG; Gershenson DM
    Int J Gynecol Pathol; 2007 Oct; 26(4):404-9. PubMed ID: 17885490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
    Tan Y; Sinniah R; Bay BH; Singh G
    J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.